Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Must Reads In FDA Actions
FDA Actions for January/February 2018
FDA Approves Steglatro for Adults with T2D, Pfizer news release; 2017 Dec 22
FDA Actions for November/December 2017
FDA Approves Ozempic for Treatment of T2D, Novo Nordisk news release; 2017 Dec 5
FDA Approves Epinephrine Autoinjector for Infants, Kaléo news release; 2017 Nov 20
FDA Approves Fasenra for Severe Eosinophilic Asthma, AstraZeneca news release; 2017 Nov 14
Shingrix Approved for Prevention of Shingles, GSK news release; 2017 Oct 23
FDA Actions for September/October 2017
FDA Approves Fast-Acting Mealtime Insulin, Novo Nordisk news release; 2017 Sep 29
FDA Approves FreeStyle Libre System for Adults, FDA news release; 2017 Sep 27
FDA Approves Single Inhaler Triple COPD Therapy, GSK news release; 2017 Sep 18
FDA OKs Diabetes Drug Indication to Reduce CV Risk, Novo Nordisk news release; 2017 Aug 25
FDA Actions for July/August 2017
QVAR RediHaler Inhalation Aerosol Approved, Teva Pharmaceutical news release; 2017 Aug 7
FDA Approves Insulia Diabetes Management App, Voluntis news release; 2017 Jul 18
FDA Actions for May/June 2017
FDA Warns of Amputation Risk with Canagliflozin, FDA news release; 2017 May 16
Postmarket Safety Events After FDA Approvals, JAMA; 2017 May 9; Downing, Shah, et al
Tymlos Approved for Osteoporosis in Postmenopausal Women, Radius Health news release; 2017 April 28